Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled ‘obsolete’
theguardian.com
Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations
The owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials.
Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.
Continue reading...
COMENTÁRIOS